Clinical significance of N-terminal pro-brain natriuretic peptide

Chinese Medical Journal

Volumn 117, Issue 11, 2004, Pages 1716-1722

  Zhang, Xiang Yang ^a   Zhu, Ji Hong ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Biological markers; Biomedical research; Natriuretic peptides

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NATRIURETIC PEPTIDE TYPE C; PROTEINASE; RENIN; URODILATIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CIRCULATION; DIAGNOSTIC TEST; DIASTOLE; GENE EXPRESSION; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART SURGERY; HEART VENTRICLE REMODELING; HUMAN; MEDICAL DECISION MAKING; NONHUMAN; PEPTIDE ANALYSIS; PROGNOSIS; PROTEIN FAMILY; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; SYSTOLE;

ANIMALS; DIASTOLE; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; PROGNOSIS; SYSTOLE;

EID: 10244255104     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-328.
2. Sudoh T, Kangawa K, Minamino N, et al. A new natriuretic peptide in porcine brain. Nature 1988;332:78-81.
3. Pemberton CJ, Johnson ML, Yandle TG, et al. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension 2000;36:355-359.
4. Chen HH, Burnett JC Jr. C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol 1998;32 Suppl 3:s22-s28.
5. Chen G, Liu N, Zhou A, et al. The role of hypertension-related gene in aortic vascular smooth muscle cells from mice and rats. Chin Med J 2001;114:833-836.
6. Wei CM, Kim CH, Khraibi AA, et al. Atrial natriuretic peptide and C-type natriuretic peptide in spontaneously hypertensive rats and their vasorelaxing actions in vitro. Hypertension 1994;23(6 Pt 2):903-907.
7. Feng HS, Zang YM, Zhu MZ, et al. Comparison of vasorelaxing actions of vasonatrin peptide, C-type natriuretic peptide and atrial natriuretic peptide. Acta Physiologica Sinica 1999;51:515-520.
8. Yu J, Zhu MZ, Wei GZ, et al. Vasorelaxing role of vasonatrin peptide in human intramammary artery in vitro. Acta Physiologica Sinica 2003;55:187-190.
9. Dong MQ, Zhu MZ, Yu J, et al. Comparison of inhibitory effects of three natriuretic peptides on the proliferation of pulmonary artery smooth muscle cells of rats. Acta Physiologica Sinica 2000;52:252-254.
10. Hirose S, Hagiwara H, Takei Y. Comparative molecular biology of natriuretic peptide receptors. Can J Physiol Pharmacol 2001;79:665-672.
11. Hunt PJ, Richards AM, Nicholls MG, et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997;47:287-296.
12. McCullough PA, Sandberg KR. Sorting out the evidence on natriuretic peptides. Rev Cardiovasc Med 2003;4 Suppl 4: s13-s19.
13. Wang TJ, Larson MG, Levy D, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002;90:254-258.
14. Campbell DJ, Mitchelhill KI, Schlicht SM, et al. Plasma amino-terminal pro-brain natriuretic peptide: a novel approach to the diagnosis of cardiac dysfunction. J Card Fail 2000;6:130-139.
15. Sirithunyanont C, Leowattana W, Sukumalchantra Y, et al. Role of the plasma brain natriuretic peptide in differentiating patients with congestive heart failure from other diseases. J Med Assoc Thai 2003;86 Suppl 1:s87-s95.
16. Zhang XY, Liu GSh, Zeng Q et al. BNP1-76 level in hypertensive. Chin J Gen Pract (Chin) 2003;2:42-44.
17. Pereira-Barretto AC, de Oliveira MT Jr, Franco FG, et al. ProBNP for stratifying patients with heart failure. Arq Bras Cardiol 2003;81:239-248.
18. Hobbs FD, Davis RC, Roalfe AK, et al. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ 2002;324:1498.
19. Cosin Aguilar J, Hernandiz Martinez A, Diez Gil JL, et al. Value of NTproBNP concentration in an out-of-hospital adult population. Rev Esp Cardiol 2003;56:236-244.
20. Nousiainen T, Vanninen E, Jantunen E, et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med 2002;251: 228-234.
21. Pfister R, Scholz M, Wielckens K, et al. The value of natriuretic peptides NT-pro-BNP and BNP for the assessment of left-ventricular volume and function. A prospective study of 150 patients. Dtsch Med Wochenschr 2002;127:2605-2609.
22. Alehagen U, Lindstedt G, Eriksson H, et al. Utility of the amino-terminal fragment of pro-brain natriuretic peptide in plasma for the evaluation of cardiac dysfunction in elderly patients in primary health care. Clin Chem 2003;49:1337-1346.
23. Rivera M, Cortes R, Mora V, et al. NT-proBNP and atrioventricular plane displacement. Relationship and diagnostic implications. Rev Esp Cardiol 2003;56: 1043-1049.
24. Talwar S, Squire IB, Davies JE, et al. Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high risk population. Eur Heart J 1999;20:1736-1744.
25. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107:2440-2445.
26. Charles CJ, Elliott JM, Nicholls MG, et al. Natriuretic peptides maintain sodium homoeostasis during chronic volume loading post-myocardial infarction in sheep. Clin Sci (Lond) 2003;104:429-436.
27. Rademaker MT, Cameron VA, Charles CJ, et al. Neurohormones in an ovine model of compensated postinfarction left ventricular dysfunction. Am J Physiol Heart Circ Physiol 2000;278:H731-H740.
28. Talwar S, Squire IB, Downie PF, et al. Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. Eur Heart J 2000;21:1514-1521.
29. Hartmann F, Kurowski V, Maghsoudi A, et al. Plasma catecholamines and N-terminal proBNP in patients with acute myocardial infarction undergoing primary angioplasty. Relation to left ventricular function and clinical outcome. Z Kardiol 2003;92:73-81.
30. Magga J, Puhakka M, Hietakorpi S, et al. Atrial natriuretic peptide, B-type natriuretic peptide and serum collagen markers after acute myocardial infarction. J Appl Physiol 2004;96:1306-1311.
31. Nilsson JC, Groenning BA, Nielsen G, et al. Left ventricular remodeling in the first year after acute myocardial infarction and the predictive value of N-terminal pro brain natriuretic peptide. Am Heart J 2002;143:696-702.
32. Palmer BR, Pilbrow AP, Yandle TG, et al. Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarction. J Am Coll Cardiol 2003;41:729-736.
33. O'Brien RJ, Squire IB, Demme B, et al. Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF. Eur J Heart Fail 2003;5:499-506.
34. Maewal P, de Lemos JA. Natriuretic Peptide hormone measurement in acute coronary syndromes. Heart Fail Rev 2003;8:365-368.
35. Jernberg T, Stridsberg M, Venge P, et al. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002;40:437-445.
36. Pruszczyk P, Kostrubiec M, Bochowicz A, et al. N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism. Eur Respir J 2003;22.649-653.
37. Kucher N, Printzen G, Doernhoefer T, et al. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 2003; 107: 1576-1580.
38. Talwar S, Downie PF, Squire IB Plasma N-terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis. Eur J Heart Fail 2001;3:15-19.
39. Qi W, Mathisen P, Kjekshus J, et al. The effect of aortic valve replacement on N-terminal natriuretic propeptides in patients with aortic stenosis. Clin Cardiol 2002;25:174-180.
40. Gerber IL, Stewart RA, Legget ME, et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 2003;107:1884-1890.
41. Qi W, Mathisen P, Kjekshus J, et al. Natriuretic peptides in patients with aortic stenosis. Am Heart J 2001;142:725-732.
42. McCullough PA, Sandberg KR. B-type natriuretic peptide and renal disease. Heart Fail Rev 2003;8:355-358.
43. Siebenhofer A, Ng LL, Plank J, et al. Plasma N-terminal pro-brain natriuretic peptide in type 1 diabetic patients with and without diabetic nephropathy. Diabet Med 2003;20:535-539.
44. Mukerjee D, Yap LB, Holmes AM, et al. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med 2003;97:1230-1236.
45. Henriksen JH, Gotze JP, Fuglsang S, et al. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003;52:1511-1517.
46. Rossi A, Enriquez-Sarano M, Burnett JC Jr, et al. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol 2000;35:1256-1262.
47. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392-2397.
48. Hanusch-Enserer U, Hermann KM, Cauza E, et al. Effect of gastric banding on aminoterminal pro-brain natriuretic peptide in the morbidly obese. Obes Res 2003;11:695-698.
49. Meinardi MT, van Veldhuisen DJ, Gietema JA, et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 2001;19: 2746-2753.
50. Nicholls MG, Lainchbury JG, Richards AM, et al. Brain natriuretic peptide-guided therapy for heart failure. Ann Med 2001;33:422-427.
51. Richards AM, Lainchbury JG, Nicholls MG, et al. BNP in hormone-guided treatment of heart failure. Trends Endocrinol Metab 2002;13:151-155.
52. Zugck C, Haunstetter A, Kruger C, et al. Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. J Am Coll Cardiol 2002;39:1615-1622.
53. Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 2002;288:1252-1259.
54. Leowattana W, Ong-Ajyooth L, Taruangsri P, et al. Circulating N-terminal pro-brain natriuretic peptide and cardiac troponin T in chronic dialysis patients. J Med Assoc Thai 2003; 86 Suppl 1:s52-s58.
55. Masson S, Vago T, Baldi G, et al. Comparative measurement of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure. Clin Chem Lab Med 2002;40:761-763.
56. Schulz H, Langvik TA, Lund Sagen E, et al. Radioimmunoassay for N-terminal probrain natriuretic peptide in human plasma. Scand J Clin Lab Invest 2001;61: 33-42.
57. Goetze JP, Christoffersen C, Perko M, et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 2003;17:1105-1107.
58. Shimizu H, Masuta K, Asada H, et al. Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta 2003;334:233-239.
59. Yeo KT, Wu AH, Apple FS, et al Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003;338:107-115.
60. Quaschning T, Galle J, Wanner C. Vasopeptidase inhibition: a new treatment approach for endothelial dysfunction. Kidney Int Suppl 2003;(84):s54-s57.